Objective:

To evaluate the association of tirzepatide and dulaglutide with outcomes for an expanded 6-component composite cardiorenal end point.

Approach:

• Study Design: This was an active comparator, randomized double-blind global trial involving 640 sites across multiple countries.
• Participants: The study included patients aged 40 years and older who had type 2 diabetes and established atherosclerotic cardiovascular disease, ensuring a population at high risk for cardiorenal complications.
• Intervention: Participants were randomly assigned to receive either tirzepatide or dulaglutide in a 1:1 ratio, with both medications administered via weekly subcutaneous self-injection.
• Endpoints: The primary end point was defined as the first occurrence of a 6-component composite of cardiorenal adverse outcomes, which included cardiovascular death, myocardial infarction (MI), stroke, hospitalization for heart failure, worsening renal function, and the need for renal replacement therapy.

Key Findings:

• Tirzepatide demonstrated noninferiority to dulaglutide with respect to the 3-component composite end point of cardiovascular death, MI, or stroke. This suggests that tirzepatide may provide similar cardiovascular protection as dulaglutide in this patient population.

Interpretation:

The findings indicate that both tirzepatide and dulaglutide are effective in managing cardiovascular risk in diabetic patients with existing cardiovascular conditions. The noninferiority of tirzepatide to dulaglutide in the primary cardiovascular outcomes is particularly noteworthy, as it supports the potential use of tirzepatide as a viable treatment option in this high-risk group.

Limitations:

• The analysis was a post hoc evaluation, which may introduce biases and limit the strength of the conclusions drawn.
• The trial's primary end point was restricted to a 3-component composite, which may not fully capture the broader spectrum of cardiorenal outcomes.

Conclusion:

This study provides a comparative analysis of the cardiorenal effects of tirzepatide and dulaglutide in diabetic patients with cardiovascular conditions, highlighting the potential of tirzepatide as an effective treatment option alongside dulaglutide.